Molecular Partners AG(MOLN) - 2024 Q2 - Earnings Call Presentation

CD123 MP0533 Induces Specific Killing of AML Cells 10 -2 10 -1 10 0 10 1 10 2 10 3 10 0 25 50 75 100 % cell killing 4 10 5 Concentration [pM] CD33+CD70+ CD123+ CD123 CD70 CD33 CD33 CD123 CD70 Patient population AML or MDS/AML R/R to HMA, induction CT or allogenic HSCT N=20–45 patients 21 Effective radioligands deliver a sufficiently large dose of radioactivity to the tumor for cell killing, while sparing healthy tissues Therapeutic Radioisotope Linker Ligand Therapeutic radioisotope: DNA damage to kill tumo ...